Clinical Trial Update: Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of docetaxel and cirmtuzumab in metastatic castration-resistant prostate cancer has been terminated. The sponsor for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cirmtuzumab (cirmtuzumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of California, San Diego | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: TERMINATED